Our Products News
-
Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023April 20, 2023 -
Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in AustraliaSuzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.February 9, 2023 -
Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.Suzhou Ribo Life Science Co., Ltd. announced the company has received the approval from the CDE of the NMPA for the clinical trial application of its innovative PCKS9 targeting oligonucleotide drug product RBD7022 to conduct the First-In-Human clinical trial in China.September 20, 2022 -
Ribo Completed Two Phase II Clinical Studies in China for Evaluation of Effects of ISIS 449884 in Patients with Type 2 Diabetes Mellitus on Either Life-Style Intervention Only or Metformin Background TreatmentSuzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).February 22, 2022 -
Ribo's siRNA Drug RBD1016 for the Treatment of Chronic Hepatitis B Has Completed a Clinical Study for Safety and Pharmacokinetic Evaluation in Healthy SubjectsRibo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.January 18, 2022 -
Ribo obtained an implied license for clinical trials of its new drug for treatment of metastatic prostate cancerSuzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.August 6, 2020